Investors might want to bet on Gain Therapeutics, Inc. (GANX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. ...

会议主要讨论的核心内容 - 公司最近发生的管理层变动,包括前CEO Matthias Alder离职,公司CFO Gene Mack被任命为临时CEO,同时公司创始人兼董事长Khalid Islam将担任执行董事长,协助管理团队推进临床开发和监管策略 [6][7] - 公司最近完成了1100万美元的公开发行,募集资金将用于继续推进GBA1帕金森病候选药物GT-02287的临床和非临床开发,以及公司的一般经营用途 [8][9] - 公司计划启动GT-02287的1b期临床试验,这将是该药物首次在帕金森病患者中进行评估,主要目的是评估药物的药代动力学、药效学、安全性和耐受性,以及对帕金森病生物标志物的影响 [10] - 公司之前完成的1期单剂量和多剂量试验结果显示,GT-02287在健康受试者中表现出良好的安全性和耐受性,为其成为最佳-in-class候选药物提供支持 [11] - 公司最新的前临床数据显示,GT-02287在GBA1帕金森病小鼠模型中可改善认知功能,这对于伴有认知功能障碍的帕金森病患者具有重要意义 [13][14] - 公司对GT-02287作为帕金森病疾病修饰治疗的潜力充满信心,期待在即将开始的1b期试验中看到这些潜在益处在患者身上的体现 [15] 问答环节重要的提问和回答 无相关内容

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Participants can join the conference call through the News and Events section of the Comp ...

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Participants can join the conference call through the News and Events section of the Com ...

Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the C ...

Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder’s departure, the ...

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024. The poster describes improvement in cognitive performance and activities of daily living associated with administration of GT-02287 the Comp ...

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024. The poster describes improvement in cognitive performance and activities of daily living associated with administration of GT-02287 the Com ...

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024. Presentation De ...

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024. Presentation D ...